Neumirna Overview
- Year Founded
-
2020
- Status
-
Private
- Employees
-
18
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
8
Neumirna General Information
Description
Developer of RNA-based therapies designed for complex neurological diseases. The company's technology utilizes a proprietary platform for targeted intrathecal delivery of antisense oligonucleotides to modulate microRNAs, enabling healthcare professionals to provide disease-modifying treatments for patients with drug-resistant epilepsy and parkinson's disease.
Contact Information
Website
www.neumirna.comCorporate Office
- A.C. Meyers Vænge 15
- 2450 Copenhagen
- Denmark
Corporate Office
- A.C. Meyers Vænge 15
- 2450 Copenhagen
- Denmark
Neumirna Timeline
Neumirna Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | 16-Nov-2026 | Completed | Generating Revenue | |||
| 4. Later Stage VC (Series A) | 08-Jan-2025 | Completed | Generating Revenue | |||
| 3. Grant | 29-Feb-2024 | Completed | Generating Revenue | |||
| 2. Grant | 01-Aug-2023 | $650K | $1.21M | Completed | Generating Revenue | |
| 1. Early Stage VC | 29-Nov-2021 | $1.21M | $1.21M | Completed | Generating Revenue |
Neumirna Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | ||||||||
| Ordinary | 5,125 | $136.34 | $136.34 | 1x | $136.34 | 2.64% | ||
| Ordinary | 3,695 | $109.07 | $109.07 | 1x | $109.07 | 1.91% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Neumirna Patents
Neumirna Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026195666-A1 | Treatment of comorbidities associated with epilepsy | Pending | 17-Mar-2025 | ||
| WO-2026068729-A1 | Antimir-27b for treatment of parkinson's disease | Pending | 26-Sep-2024 | ||
| AU-2022329462-A1 | Antisense oligonucleotides targeting adenosine kinase | Inactive | 19-Aug-2021 | ||
| CA-3228833-A1 | Antisense oligonucleotides targeting adenosine kinase | Pending | 19-Aug-2021 | ||
| EP-4388096-A1 | Antisense oligonucleotides targeting adenosine kinase | Pending | 19-Aug-2021 | C12N15/1137 |
Neumirna Signals
Neumirna Investors (8)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| European Innovation Council | Accelerator/Incubator | |||
| Angelini Ventures | Corporate Venture Capital | Minority | ||
| Iaso Ventures | Venture Capital | Minority | ||
| Invivo Partners | Venture Capital | Minority | ||
| Welfare Tech Invest | Venture Capital | Minority |
Neumirna FAQs
-
When was Neumirna founded?
Neumirna was founded in 2020.
-
Where is Neumirna headquartered?
Neumirna is headquartered in Copenhagen, Denmark.
-
What is the size of Neumirna?
Neumirna has 18 total employees.
-
What industry is Neumirna in?
Neumirna’s primary industry is Drug Discovery.
-
Is Neumirna a private or public company?
Neumirna is a Private company.
-
What is Neumirna’s current revenue?
The current revenue for Neumirna is .
-
How much funding has Neumirna raised over time?
Neumirna has raised $24.5M.
-
Who are Neumirna’s investors?
European Innovation Council, Angelini Ventures, Iaso Ventures, Invivo Partners, and Welfare Tech Invest are 5 of 8 investors who have invested in Neumirna.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process